Skip to main content
Equibles
KNSA logo

KNSA · Kiniksa Pharmaceuticals International, plc · Metrics

Track KNSA — free

Use KNSA with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research KNSA.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$76.40 +0.61 (+0.80%)
Russell 2000 member Rebalance outlook locked
Market Cap
$11.72B
Shares
156.05M
Volume · Oct 5 246.51K Avg daily vol (3M) 602.43K

KNSA metrics

78 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$75.79
Market cap
$11.72B

Price action

20 metrics
Price change (1W)
+0.9%
Price change (30D)
-1.7%
Price change (3M)
+17.4%
Price change (6M)
+55.2%
Price change (YTD)
+83.7%
Price change (1Y)
+102.3%
Trailing year
Price change (5Y)
+560.2%
52-week high
$80.92
52-week low
$37.01
Change from 52-week high
-6.3%
Change from 52-week low
+104.8%
Annualized volatility
49.5%
Annualized volatility (3M)
60.8%
Beta
0.3
RSI (14D)
47.9
Price vs SMA 50
-1.6%
Price vs SMA 200
+34.8%
Avg volume (3M)
602,431
Relative volume
0.6
Average dollar volume
$44.68M

Company

3 metrics
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Shares outstanding
156.05M

Valuation

12 metrics
P / E (TTM)
83.3
Trailing earnings · reciprocal yield 1.2%
PEG ratio
0.6
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
15.5×
reciprocal yield 6.4%
P / book
19.3
reciprocal yield 5.2%
FCF yield
1.4%
TTM · current market cap
Buyback yield
—
P / FCF
71.3
reciprocal yield 1.4%
P / operating cash flow
70.6
reciprocal yield 1.4%
Earnings yield
0.6%

Historical valuation

8 metrics
P / E historical average (3Y)
60.8×
reciprocal yield 1.6%
P / E historical average (5Y)
47.1×
reciprocal yield 2.1%
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
0.0%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-07-28

Profitability

9 metrics
Gross margin
89.3%
Operating margin
12.4%
Trailing 12 months
Net margin
9.7%
Gross profit (TTM)
—
Operating profit (TTM)
$93.22M
Net income (TTM)
$73.06M
Trailing 12 months
Diluted EPS (TTM)
$0.91
FCF margin
21.8%
Effective tax rate
31.1%

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
—

Growth

11 metrics
Revenue growth YoY
+55.5%
Year over year
Net income growth YoY
+164.6%
Revenue (TTM)
$754.04M
Trailing 12 months
EPS growth YoY
+145.5%
Shares change YoY
+8.2%
Year over year · more shares
Revenue CAGR (3Y)
+45.5%
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
-33.9%
EPS CAGR (5Y)
—
FCF CAGR (3Y)
+188.1%
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
12.1%
Return on assets
8.9%
Debt / equity
—
Current ratio
3.8
EBITDA (TTM)
$94.89M
Free cash flow (TTM)
$164.23M
Quick ratio
3.3
Interest coverage
—
Net debt / EBITDA
-4.9
Return on invested capital
—
Trailing 12 months
Net cash
$468.09M
Latest balance sheet
Cash & equivalents
$189.95M
Total assets
$825.28M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$165.86M
Capital expenditures (TTM)
$1.63M
R&D (TTM)
$105.00M
SG&A (TTM)
$213.89M
Stock compensation (TTM)
$39.31M
R&D / revenue
13.9%
Stock compensation / revenue
5.2%

Ownership (13F)

3 metrics
13F filers
269
13F filer change QoQ
+40
Institutional ownership
30.3%

Short interest

3 metrics
Short interest
2.5%
Latest settlement · 7.2 days to cover
Days to cover
7.2d
Short-squeeze score
58 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$668,472
Insider-sentiment score
50 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1730430 CUSIP G52694109 13F (30d) 5 filings 5 filers Visit website Investor relations